Most of the time, Merck & Co’s Keytruda (pembrolizumab) has been a consistent performer across a range of cancers – but it has produced an uncharacteristic failure in tough to treat triple negative breast cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,